ZD1839 induces p15INK4b and causes G1 arrest by inhibiting the mitogen-activated protein kinase/extracellular signal-regulated kinase pathway

Molecular Cancer Therapeutics

Volumn 6, Issue 5, 2007, Pages 1579-1587

  Koyama, Makoto ^a   Matsuzaki, Youichirou ^a   Yogosawa, Shingo ^a   Hitomi, Toshiaki ^a   Kawanaka, Mayumi ^a   Sakai, Toshiyuki ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; CYCLIN DEPENDENT KINASE INHIBITOR 2B; GEFITINIB; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B INHIBITOR; ANTINEOPLASTIC AGENT; FLAVONOID; QUINAZOLINE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; COLON CANCER; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; FIBROBLAST; HUMAN; HUMAN CELL; KERATINOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETINOBLASTOMA; UPREGULATION; WILD TYPE; BIOLOGICAL MODEL; CELL CYCLE; CELL PROLIFERATION; GENE EXPRESSION REGULATION; METABOLISM; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P15; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FLAVONOIDS; G1 PHASE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MAP KINASE SIGNALING SYSTEM; MODELS, BIOLOGICAL; PHOSPHORYLATION; QUINAZOLINES; SIGNAL TRANSDUCTION;

EID: 34250736348     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-06-0814     Document Type: Article

References (45)

1. 1 cell-cycle control and cancer. Nature 2004;432:298-306.
2. 1 cyclins. Cell 1993;73:1059-65.
3. Dowdy SF, Hinds PW, Louie K, Reed SI, Arnold A, Weinberg RA. Physical interaction of the retinoblastoma protein with human D cyclins. Cell 1993;73:499-511.
4. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993;366:704-7.
5. Hirai H, Roussel MF, Kato J, Ashmun RA, Sherr CJ. Novel INK4 proteins, p19 and p18, are specific inhibitors of the cyclin D-dependent kinases CDK4 and CDK6. Mol Cell Biol 1995;15:2672-81.
6. Roussel MF. The INK4 family of cell cycle inhibitors in cancer. Oncogene 1999;18:5311-7.
7. Irwin MS, Kaelin WG. p53 family update: p73 and p63 develop their own identities. Cell Growth Differ 2001;12:337-49.
8. Franklin DS, Godfrey VL, Lee H, et al. CDK inhibitors p18(INK4c) and p27(Kip1) mediate two separate pathways to collaboratively suppress pituitary tumori genesis. Genes Dev 1998;12:2899-911.
9. INK4c cell cycle inhibitors in proliferation and tumorigenesis. EMBO J 2000;19:3496-506.
10. Ink4a confers susceptibility to metastatic melanoma in mice. Nature 2001;413:83-6.
11. Merlo A, Herman JG, Mao L, et al. 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/ CDKN2/MTS1 in human cancers. Nat Med 1995;1:686-92.
12. Esteller M, Corn PG, Baylin SB, Herman JG. A gene hypermethylation profile of human cancer. Cancer Res 2001;61:3225-9.
13. INK4B is a potential effector of TGF-β-induced cell cycle arrest. Nature 1994;371:257-61.
14. INK4A tumor suppressor genes in oxystress-induced renal cell carcinoma of rats. Oncogene 1999;18:3793-7.
15. Kurakawa E, Shimamoto T, Utsumi K, Hirano T, Kato H, Ohyashiki K. Hypermethylation of p16(INK4a) and p15(INK4b) genes in non-small cell lung cancer. Int J Oncol 2001;19:277-81.
16. Yokota T, Matsuzaki Y, Miyazawa K, Zindy F, Roussel MF, Sakai T. Histone deacetylase inhibitors activate INK4d gene through Sp1 site in its promoter. Oncogene 2004;23:5340-9.
17. INK4d gene. FEBS Lett 2004;574:171-5.
18. INK4b in HDAC inhibitor-induced growth arrest. FEBS Lett 2003;554:347-50.
19. INK4b gene. FEBS Lett 2004;576:137-40.
20. Albanell J, Codony-Servat J, Rojo F, et al. Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor α expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments. Cancer Res 2001;61:6500-10.
21. Janmaat ML, Kruyt FA, Rodriguez JA, Giaccone G. Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways. Clin Cancer Res 2003;9:2316-26.
22. Barnes CJ, Bagheri-Yarmand R, Mandal M, et al. Suppression of epidermal growth factor receptor, mitogen-activated protein kinase, and Pak1 pathways and invasiveness of human cutaneous squamous cancer cells by the tyrosine kinase inhibitor ZD1839 (Iressa). Mol Cancer Ther 2003;2:345-51.
23. Rusch V, Klimstra D, Venkatraman E, Pisters PW, Langenfeld J, Dmitrovsky E. Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor α is frequent in resectable non-small cell lung cancer but does not predict tumor progression. Clin Cancer Res 1997;3:515-22.
24. Kersemaekers AM, Fleuren GJ, Kenter GG, et al. Oncogene alterations in carcinomas of the uterine cervix: overexpression of the epidermal growth factor receptor is associated with poor prognosis. Clin Cancer Res 1999;5:577-86.
25. Anderson NG, Ahmad T, Chan K, Dobson R, Bundred NJ. ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 overexpression. Int J Cancer 2001;94:774-82.
26. Arteaga CL. Epidermal growth factor receptor dependence in human tumors: more than just expression? Oncologist 2002;7:31-9.
27. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to ZD1839. N Engl J Med 2004;350:2129-39.
28. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to ZD1839 therapy. Science 2004;304:1497-500.
29. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to ZD1839 and erlotinib. Proc Natl Acad Sci U S A 2004;101:13306-11.
30. Ogino S, Meyerhardt JA, Cantor M, et al. Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer. Clin Cancer Res 2005;11:6650-6.
31. Sambrook J, Russell DW, editors. Molecular cloning: a laboratory manual. 1st ed. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press; 2001. p. 7.42-4.
32. Janne PA, Taffaro ML, Salgia R, Johnson BE. Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma. Cancer Res 2002;62:5242-7.
33. CIP1/WAF1 in the antiproliferative effect of ZD1839 ("Iressa"), an epidermal growth factor receptor tyrosine kinase inhibitor, in head and neck squamous carcinoma cells. J Cell Physiol 2003;195:139-50.
34. Nishimura N, Furukawa Y, Sutheesophon K, et al. Suppression of ARG kinase activity by STI571 induces cell cycle arrest through upregulation of CDK inhibitor p18/INK4c. Oncogene 2003;22:4074-82.
35. 1 arrest in oral squamous carcinoma cell lines. Oncology 2002;63:92-8.
36. INK4b. Mol Cell Biol 2000;20:2915-25.
37. Wen-Sheng W. ERK signaling pathway is involved in p15INK4b/ p16INK4a expression and HepG2 growth inhibition triggered by TPA and Saikosaponin a. Oncogene 2003;22:955-63.
38. INK4b. Nat Cell Biol 2001;3:400-9.
39. Shaw G, Kamen R. A conserved AU sequence from the 3′ untranslated region of GM-CSF mRNA mediates selective mRNA degradation. Cell 1986;46:659-67.
40. Sirenko OI, Lofquist AK, DeMaria CT, Morris JS, Brewer G, Haskill JS. Adhesion-dependent regulation of an AU-rich element-binding activity associated with AUF1. Mol Cell Biol 1997;17:3898-906.
41. Sheng H, Shao J, DuBois RN. K-Ras-mediated increase in cyclo-oxygenase 2 mRNA stability involves activation of the protein kinase B. Cancer Res 2001;61:2670-5.
42. Cappuzzo F, Magrini E, Ceresoli GL, et al. Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 2004;96:1133-41.
43. Ono M, Hirata A, Kometani T, et al. Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation. Mol Cancer Ther 2004;3:465-72.
44. Sakai T. Molecular cancer epidemiology - the present status and future possibilities. Jpn J Hygiene 1996;50:1036-46.
45. Sowa Y, Sakai T. Butyrate as a model for "Gene-regulating chemo-prevention and chemotherapy". Biofactors 2000;2:283-7.